Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...
Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...
CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...
Verywell Health on MSN
Leukemia symptoms by stage and type
Early symptoms of leukemia include headaches, fatigue, and fever. In advanced stages, you may experience red skin spots and ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results